Ana-Marija Bukovica Petrc

Dr. Ana-Marija Bukovica Petrc


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2025 in Genes
Verified
Journal Article
Open access
PDF file
DVDamir Vučinić
Damir Vučinić
APAna-Marija Bukovica Petrc
Ana-Marija Bukovica Petrc
IAIvona Antončić
Ivona Antončić
Maja Kolak RadojčićMaja Kolak Radojčić
Maja Kolak Radojčić
MLMatea Lekić
Matea Lekić
FCFelipe Counago
Felipe Counago
Stereotactic body radiotherapy (SBRT) delivers ablative radiation doses with sub-millimeter precision. Radiogenomic studies, meanwhile, provide insights into how tumor-intrinsic genetic factors influence responses to such high-dose treatments. This review explores the radiobiological mechanisms underpinning SBRT efficacy, emphasizing the roles of DNA damage response (DDR) pathways, tumor suppressor gene alterations, and inflammatory signaling in shaping tumor radiosensitivity or resistance. SBRT induces complex DNA double-strand breaks (DSBs) that robustly activate DDR signaling cascades, particularly via the ATM and ATR kinases. Tumors with proficient DNA repair capabilities often resist SBRT, whereas deficiencies in key repair genes can render them more susceptible to radiation-induced cytotoxicity. Mutations in tumor suppressor genes may impair p53-dependent apoptosis and disrupt cell cycle checkpoints, allowing malignant cells to evade radiation-induced cell death. Furthermore, SBRT provokes the release of pro-inflammatory cytokines and activates innate immune pathways, potentially leading to immunogenic cell death and reshaping the tumor microenvironment. Radiogenomic profiling has identified genomic alterations and molecular signatures associated with differential responses to SBRT and immune activation. These insights open avenues for precision radiotherapy approaches, including the use of genomic biomarkers for patient selection, the integration of SBRT with DDR inhibitors or immunotherapies, and the customization of treatment plans based on individual tumor genotypes and immune landscapes. Ultimately, these strategies aim to enhance SBRT efficacy and improve clinical outcomes through biologically tailored treatment. This review provides a comprehensive summary of current knowledge on the genetic determinants of response to stereotactic radiotherapy and discusses their implications for personalized cancer treatment.

Verified
Journal Article
Open access
PDF file
ISIva Skocilic
Iva Skocilic
Marin GolčićMarin Golčić
Marin Golčić
APAna-Marija Bukovica Petrc
Ana-Marija Bukovica Petrc
Maja Kolak RadojčićMaja Kolak Radojčić
Maja Kolak Radojčić
DKDoris Kolovrat
Doris Kolovrat
IMIvana Mikolasevic
Ivana Mikolasevic
Background: There are limited real-world data (RWD) regarding the use of cyclin-dependent kinase (CDK) 4/6 inhibitors in western Balkan. The aim of our study was thus to analyze factors influencing progression-free survival (PFS) and overall survival (OS), along with the differences in adverse effects of CDK 4/6 therapy in a tertiary healthcare center in Croatia. Methods: We evaluated medical and demographic data for 163 consecutive patients with metastatic breast cancer treated with CDK4/6 inhibitors for at least one month, from October 2018, after the drug became available in Croatia. Eligible patients in our study were those patients who were treated with palbociclib, ribociclib, or abemaciclib. Results: The median PFS of CDK4/6 inhibitors treatment was 2.2 years (95% CI 1.8–3.3), with the longest ongoing treatment for 5.4 years. Treatment with CDK4/6 inhibitors in the first line was associated with a longer PFS compared to the second line or beyond (HR 0.50, 95% CI 0.3–0.9), and patients without liver metastasis exhibited longer survival compared to patients with liver metastasis (HR 0.46, 95% CI 0.2–0.8) (both p < 0.05). Regarding the choice of CDK4/6 inhibitors, ribociclib exhibited longer PFS compared to palbociclib (HR 0.49, 95% CI 0.29–0.82) (p = 0.0032), although the effect was not statistically significant when separating patients who were treated with CDK4/6 inhibitors in the first-line (HR 0.59, 95% CI 0.29–1.2), or second- or later-line therapy (0.49, 95% CI 0.15–1.55); the trend was present in both lines, however. The presence of liver metastasis (p = 0.04), initial luminal A grade (p = 0.039), and time to metastasis up to 5 years from the initial cancer (p = 0.002) were the only factors that remained statistically significant for PFS in multivariate analysis. Median OS since the diagnosis of metastatic disease was 4.5 years (95% CI 3.9–6.3), median OS since the start of CDK4/6 inhibitors treatment was 3.7 years (95% CI 3.4–4.4), while median OS from initial cancer diagnosis was 15.8 years (95% CI 13.8–18.3). There was no difference in OS based on the choice of CDK4/6 inhibitor (p = 0.44) or the adjuvant hormonal therapy (p = 0.12), although a nonsignificant trend for better OS with ribociclib was present for both regardless of whether it was in first- or second/later-line therapies (p > 0.05). In a multivariate analysis, only the presence of liver metastasis (p = 0.0003) and time to metastasis under 5 years from primary breast cancer (p = 0.03) were associated with a worse OS. Conclusions: Our study provides the RWD with the use of CDK4/6 inhibitors in the treatment of metastatic HR+/HER2− breast cancer. To our best knowledge, there are limited RWD regarding CDK 4/6 inhibitors use in western Balkan; thus, our study provides valuable data from everyday clinical practice for this region of Europe, bridging the gap between randomized clinical trials and clinical reality in western Balkan.

31 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
SSSanja Stojsavljevic Shapeski
Sanja Stojsavljevic Shapeski
GPGoran Poropat
Goran Poropat
ISIva Skocilic
Iva Skocilic
PBPetra Puz Britvic
Petra Puz Britvic
JPJuraj Prejac
Juraj Prejac
IMIvana Mikolasevic
Ivana Mikolasevic
Parallel to the increased use of immune checkpoint inhibitors (ICIs), the incidence of immune-related adverse events (irAEs) is also increasing. Almost all organs can be affected by the immune-mediated response, including the liver, pancreas and biliary tract. Immune-Mediated Hepatitis is a common complication of ICI therapy, while cholangitis, cholecystitis and pancreatic involvement are less frequent. Emerging evidence from clinical trials and real-world data series helps us better understand the risk factors, diagnostic challenges and management strategies for these irAEs. With wider use of ICIs, more data are also available on the management of special populations with comorbidities and patients with difficult-to-treat or treatment-resistant adverse events, but larger prospective studies and more robust evidence are required for further recommendations on their management and ICI reintroduction. In clinical practice, a multidisciplinary approach to the management of ICI-mediated complications is advised, with close collaboration among specialties such as oncologists, gastroenterologists or hepatologists, pathologists, radiologists and others. While Immune-Mediated Hepatitis is a common irAE of ICI therapy, pancreato-biliary involvement is often overlooked and underdiagnosed. These irAEs require multimodal management, development of new biomarkers and prediction models to facilitate decision-making and improve patient outcomes.